{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:01:48Z","timestamp":1790240508292,"version":"4.1.0"},"reference-count":65,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,2,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant\n                      <jats:italic toggle=\"yes\">Streptococcus pneumoniae,<\/jats:italic>\n                      methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli. It also has activity against many nontuberculous mycobacterium (NTM) species. It is available both orally and intravenously, which allows for feasible switch therapy. This review will assess the antimicrobial activity, pharmacology, safety, and clinical efficacy of omadacycline and present the opinions of the authors on where to position omadacycline for clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01087-24","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:00:42Z","timestamp":1737018042000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on\n                    <i>M. abscessus<\/i>\n                    )"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6080-467X","authenticated-orcid":true,"suffix":"Jr.","given":"Thomas M.","family":"File","sequence":"first","affiliation":[{"name":"Division of Infectious Disease, Summa Health","place":["Akron, USA"]},{"name":"Section of Infectious Diseases, Northeast Ohio Medical University","place":["Rootstown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5374","authenticated-orcid":false,"given":"Julio A.","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Louisville","place":["Louisville, USA"]},{"name":"Norton Infectious Diseases Institute, Norton Healthcare","place":["Louisville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-0025","authenticated-orcid":false,"given":"Ashley M.","family":"Wilde","sequence":"additional","affiliation":[{"name":"Norton Infectious Diseases Institute, Norton Healthcare","place":["Louisville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Nuzyra: highlights of prescribing information. Available from: https:\/\/www.nuzyra.com\/nuzyra-pi.pdf"},{"key":"e_1_3_2_3_2","unstructured":"Paratek pharmaceuticals announces FDA orphan drug designation for NUZYRA (omadacycline) for the treatment of infections caused by nontuberculous mycobacteria. 2021. Available from: https:\/\/www.globenewswire.com\/en\/news-release\/2021\/08\/18\/2283087\/33636\/en\/Paratek-Pharmaceuticals-Announces-FDA-Orphan-Drug-Designation-for-NUZYRA-omadacycline-for-the-Treatment-of-Infections-Caused-by-Nontuberculous-Mycobacteria.html"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics5040032"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz395"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac356"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02213-21"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02551-17"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_2_15_2","unstructured":"Omadacycline injection and oral products. U.S. Food & Drug Administration. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00824-23"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad170"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1666"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00595-24"},{"key":"e_1_3_2_20_2","volume-title":"33rd European Congress of Clinical Microbiology & Infectious Diseases","author":"Huband M","year":"2023","unstructured":"Huband M, Rhomberg PR, Blankers C, Pfaller MA, Castanheira M. 2023. In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programme. 33rd European Congress of Clinical Microbiology & Infectious Diseases. Copenhagen, Denmark"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01686-23"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.08.012"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04616-7"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00542-22"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01603-19"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01947-20"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03654-22"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz398"},{"key":"e_1_3_2_31_2","unstructured":"Paratek pharmaceuticals announces positive top-line efficacy and safety data from post-marketing study of NUZYRA (omadacycline) for patients with moderate to severe community-acquired bacterial pneumonia. 2024. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/07\/18\/2915177\/0\/en\/Paratek-Pharmaceuticals-Announces-Positive-Top-line-Efficacy-and-Safety-Data-from-Post-Marketing-Study-of-NUZYRA-omadacycline-for-Patients-with-Moderate-to-Severe-Community-Acquire.html"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00320-16"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221089007"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00522-20"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01440-21"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01431-20"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01581-18"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.26226\/morressier.56d6be7ad462b80296c97dee"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz397"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab135"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.01.032"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1225710"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00587-4"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa558"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab136"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106263"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01704-21"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790767"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad104"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa415"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab002"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2023.e01703"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.06.061"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad335"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2303286"},{"key":"e_1_3_2_59_2","volume-title":"Treatment of community-acquired pneumonia in adults in the outpatient setting","author":"File TM","year":"2014","unstructured":"File TM. 2014. Edited by T. Post. Treatment of community-acquired pneumonia in adults in the outpatient setting. UpToDate, Waltham, Mass. www.uptodate.com."},{"key":"e_1_3_2_60_2","volume-title":"Treatment of community-acquired pneumonia in adults who require hospitalization","author":"File TM","year":"2014","unstructured":"File TM. 2014. Edited by T. Post. Treatment of community-acquired pneumonia in adults who require hospitalization. UpToDate, Waltham, Mass. www.uptodate.com."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01005-w"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac030"},{"key":"e_1_3_2_63_2","volume-title":"Acute cellulitis and erysipelas in adults: treatment","author":"Spelman D","year":"2014","unstructured":"Spelman D. 2014. Edited by T. Post. Acute cellulitis and erysipelas in adults: treatment. UpToDate, Waltham, Mass. www.uptodate.com."},{"key":"e_1_3_2_64_2","unstructured":"Lexidrug. Omadacycline average wholesale price. Medi-Span. Available from: https:\/\/www.wolterskluwer.com\/en\/solutions\/uptodate\/pro\/lexidrug. Retrieved 25 Nov 2024."},{"key":"e_1_3_2_65_2","unstructured":"Mark Cuban Cost Plus Drug Company. Medications. Available from: https:\/\/costplusdrugs.com\/medications\/. Retrieved 25 Nov 2024."},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07857-7"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01087-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01087-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T18:24:50Z","timestamp":1748283890000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01087-24"}},"subtitle":[],"editor":[{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,13]]}},"alternative-id":["10.1128\/aac.01087-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01087-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"2025-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01087-24"}}